$TEM News

Tempus AI, Inc. (TEM) Analyst/Investor Day Transcript

Tempus AI Announces Upcoming Clinical Availability Of xH, Next-Gen Whole-Genome Sequencing Test

Needham Reiterates Buy on Tempus AI, Maintains $75 Price Target

BTIG Reiterates Buy on Tempus AI, Maintains $80 Price Target

Tempus AI, Inc. (TEM) Analyst/Investor Day - Slideshow

Tempus AI Announces Latest Results From Its Mission To Build Multimodal Foundation Models At The 2026 American Society Of Clinical Oncology Annual Meeting

Tempus AI Secures FDA Approval For Tumor-Only Indication For Its xT CDx Next-Gen Sequencing Platform

Why Is Tempus AI Stock Surging On Thursday?

Tempus AI (TEM) Launches ArteraAI Prostate Test, The First Externally Developed Digital Pathology Algorithm

Tempus AI: Taking Advantage Of Investor Myopia

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2026 Update

Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for "Best Overall Health Informatics Solution"

HC Wainwright & Co. Maintains Buy on Tempus AI, Lowers Price Target to $64

Is Tempus AI (TEM) The Best AI Healthcare Stock to Buy?

Tempus AI Expands Beyond Oncology With New Alzheimer’s Blood Test Alliance

BTIG Maintains Buy on Tempus AI, Lowers Price Target to $80

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense